IsoRay, Inc. (NYSEAMERICAN:ISR) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,065,703 shares, a decline of 2.9% from the January 15th total of 1,097,591 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average trading volume of 349,208 shares, the days-to-cover ratio is presently 3.1 days.
ISR opened at $0.42 on Thursday. IsoRay has a 52-week low of $0.27 and a 52-week high of $1.22.
IsoRay (NYSEAMERICAN:ISR) last issued its earnings results on Tuesday, February 12th. The healthcare company reported ($0.02) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.02). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.76 million.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Highland Private Wealth Management bought a new stake in IsoRay during the 4th quarter valued at $39,000. Vanguard Group Inc raised its position in IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after purchasing an additional 367,324 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after purchasing an additional 367,324 shares in the last quarter.
A number of equities analysts recently issued reports on ISR shares. Zacks Investment Research upgraded IsoRay from a “sell” rating to a “hold” rating in a report on Friday, November 9th. HC Wainwright restated a “buy” rating and set a $0.70 price objective on shares of IsoRay in a report on Monday, January 28th. Finally, Maxim Group cut IsoRay from a “buy” rating to a “hold” rating in a report on Friday, November 9th.
IsoRay Company Profile
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Recommended Story: Do You Need a Fiduciary?
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.